Evidence map›Paper›PMID 40500441›Full record

ArticleNature2025

RIFINs displayed on malaria-infected erythrocytes bind KIR2DL1 and KIR2DS1.

Akihito Sakoguchi, Samuel G Chamberlain, Alexander M Mørch, Marcus Widdess, Thomas E Harrison, Michael L Dustin, Hisashi Arase, Matthew K Higgins, Shiroh Iwanaga

Abstract read
In one paragraph

Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Akihito Sakoguchi *Department of Protozoology, Research Institute for Microbial Diseases, The University of Osaka, Suita, Japan.ORCID 0000-0003-4359-653X
Samuel G Chamberlain *Department of Biochemistry, University of Oxford, Oxford, UK.
Alexander M MørchKennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
Marcus WiddessKennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
Thomas E HarrisonDepartment of Biochemistry, University of Oxford, Oxford, UK.
Michael L DustinKennedy Institute of Rheumatology, University of Oxford, Oxford, UK.ORCID 0000-0003-4983-6389
Hisashi AraseDepartment of Immunochemistry, Research Institute for Microbial Diseases, The University of Osaka, Suita, Japan. arase@biken.osaka-u.ac.jp.ORCID 0000-0002-1153-3166
Matthew K HigginsDepartment of Biochemistry, University of Oxford, Oxford, UK. matthew.higgins@bioch.ox.ac.uk.ORCID 0000-0002-2870-1955
Shiroh IwanagaDepartment of Protozoology, Research Institute for Microbial Diseases, The University of Osaka, Suita, Japan. iwanaga@biken.osaka-u.ac.jp.ORCID 0000-0002-4394-7267

Funding

Wellcome Trust
6 · The paper itself

Abstract

Natural killer (NK) cells use inhibitory and activating immune receptors to differentiate between human cells and pathogens. Signalling by these receptors determines whether an NK cell becomes activated and destroys a target cell. In some cases, such as killer immunoglobulin-like receptors, immune receptors are found in pairs, with inhibitory and activating receptors containing nearly identical extracellular ligand-binding domains coupled to different intracellular signalling domains

Indexed as

ErythrocytesMalaria, FalciparumPlasmodium falciparumProtozoan ProteinsReceptors, KIRReceptors, KIR2DL1HumansKiller Cells, NaturalLigandsLymphocyte ActivationMembrane ProteinsProtein BindingSignal TransductionKIR2DL1 protein, humanKIR2DS1 protein, humanLigandsMembrane ProteinsProtozoan ProteinsReceptors, KIRReceptors, KIR2DL1RIFIN protein, Plasmodium falciparum

Identifiers

PMID40500441
PMCPMC12310515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.